UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July 4~~November 6, 2006

GAMMACAN INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-32835

(Commission File Number)

33-0956433

(IRS Employer Identification No.)

2939 Jerusalem ~~Street~~St., ~~554210 Kiryat Ono, Israel~~

Kiryat Ono 55423 Israel

(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: 972 3 ~~738 2616~~7382616

11 Ben Gurion St., 54100 Givat Shmuel, Israel

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 7.01 Regulation FD Disclosure~~-2-

OnITEM ~~July~~5.02 Departure ~~4, 2006, Maariv, a daily newspaper in Israel printed an article discussing GammaCan International, Inc.’s business. A copy~~ of ~~the~~Directors ~~article~~or isPrincipal ~~filed~~Officers; ~~as Exhibit~~Election 99.1 to, and incorporated by reference in, this report. In accordance with Regulation FD, this current report is being filed to publicly disclose all information that was provided in the article. This report under Item 7.01 is not deemed an admission as to the materiality of ~~any~~Directors; ~~information~~Appointment ~~in this report~~of ~~that is~~Principal ~~required to be disclosed solely by Regulation FD~~Officers.

~~Item~~Each 8of Elisha Martinez and Dr.01 ~~Other~~Lior ~~Events~~Soussan-Gutman resigned as members of the Board of Directors of Gammacan International, Inc. In connection with the foregoing resignations, on November 6, 2006, Steven Katz and Albert Passner were each appointed as members of the Board of Directors of Gammacan International, Inc. to fill the vacancies created.

~~The~~In ~~management~~connection with their appoint as members of ~~GammaCan~~such ~~International~~company’s Board of Directors, each ~~Inc~~of Mr. ~~reviewed~~Katz ~~the~~and ~~article~~Mr. byPassner ~~Maariv~~received ~~after~~options to purchase an aggregate itof 150,000 ~~was~~shares ~~printed.vTo~~of ~~avoid~~the ~~any~~Company’s ~~doubt~~common ~~the~~stock. ~~management~~The ofexercise ~~GammaCan~~price ~~International,~~is $0.45 per ~~Inc.~~share ~~would~~and ~~like~~shall be vested with respect to ~~add~~25% of the ~~following~~shares ~~clarifications~~after ~~which~~the ~~more accurately~~first ~~reflect~~anniversary ~~the~~of ~~statements~~his ~~Mr.~~appointment ~~Schnegelsberg~~and ~~made:~~thereupon in equal instalments for 36 months.

·Steven Katz ~~While Mr. Zeev Bronfeld was mentioned as being a major share holder of GammaCan International, Inc. he was not discussed in the context of any financings.~~

·Mr. Katz is Tothe ~~address~~president ~~the~~of ~~change~~Steven Katz & Associates, Inc., a health care and technology based management consulting firm specializing in ~~emphasis~~strategic planning, tocorporate ~~VitiGam~~development, ~~from~~new ~~GCAN~~product ~~101~~planning, ~~Mr.~~technology ~~Schnegelsberg~~licensing and structuring ~~stated~~and ~~that~~securing ~~GammaCan~~various ~~would~~forms ~~put~~of ~~all~~financing ~~its~~and ~~efforts~~has ~~into~~been ~~developing~~the ~~VitiGam~~president since 1982. From January ~~Based~~2000 onto ~~VitiGam’s~~October ~~specific~~2001 ~~anti-~~Mr. ~~melanoma~~Katz ~~activity~~was ~~seen~~also inPresident, inChief ~~vitro~~Operating Officer and a director of Senesco Technologies, Inc., an American Stock Exchange listed company engaged in the identification and development of proprietary gene technology with application to human, animal ~~experiments~~and asplant ~~well~~systems. asFrom ~~VitiGam’s~~1983 ~~anticipated~~to 1984 ~~safety~~Mr. ~~profile~~Katz ~~(comparable~~was a co-founder and Executive Vice President of S.K.Y. Polymers, Inc., a bio-materials company. Prior to ~~that~~this, Mr. Katz was Vice President and General Manager of ~~GCAN101~~a non-banking division of Citicorp. From 1976 to 1981 he held various senior management positions at National Patent Development Corporation, including President of three subsidiaries. Prior positions were with Revlon, Inc. (1975) ~~GammaCan~~and ~~anticipates~~Price ~~VitiGam~~Waterhouse & Co. (1969 to be1974). Mr. Katz received a Bachelors ~~substantially~~of ~~improved~~Business ~~drug~~Administration ~~over~~degree ~~GCAN101~~in Accounting from the City College of New York in 1969. Mr. Katz is presently a member of the Board of Directors of the following publicly-held corporations: Biophan Technologies, Inc., Nanoscience Technologies, Inc., NaturalNano, Inc. and USA Technologies, Inc. and the following private companies Expert Real Estate Services, Inc. and MDSERVE, Inc.

· Mr. Schnegelsberg in his discussion about potential markets suggested that the annual therapy cost for biologics today is between $50,000 and $80,000. He further suggested that some exceptionally active biologics could command premium pricing in the $100,000 range. VitiGam pricing was not discussed.Albert Passner

·Mr. Passner ~~GammaCan~~has ~~received~~been ~~the~~an ~~approval~~independent ofconsultant ~~the~~since ~~BIRD~~2001. ~~Foundation~~In ~~for~~addition, Mr. Passner has been a ~~$1,000,000~~member ~~grant.~~of ~~Under~~the ~~this~~board ~~grant~~of ~~GammaCan~~directors ~~International~~of Nanoscience Technologies, Inc. since 2005 and ~~Life~~a ~~Therapeutics~~member of the board of directors of USA Technologies, Inc. since ~~(and~~2006. ~~not~~From 1969 through 2001 Mr. Passner was a member of the ~~entity~~technical staff ~~identified~~of Lucent (AT&T) Bell Laboratories. Mr. Passner has a Bachelors of Science in Physics from the ~~article)~~City ~~would~~College ~~partner~~of New York in a1960 ~~joint~~and ~~study~~a Masters of Science ~~VitiGam~~in Physics from New York University in 1966.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Article printed in the Maariv Business Section on July 4, 2006

10.1 Indemnity Agreement between Gammacan International, Inc. and Steven Katz , dated as of November 13, 2006.

10.2 Indemnity Agreement between Gammacan International, Inc. and David Stevens, dated as of November 13, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GAMMACAN INTERNATIONAL, INC. /s/ Patrick Schnegelsberg Patrick SchnegelsbergChief Executive Officer Date: July 7, 2006


	GAMMACAN INTERNATIONAL, INC.

		/s/ Patrick Schnegelsberg

		Patrick Schnegelsberg Chief Executive Officer

		Date: November 13, 2006

-3-

Filing Compare · GAMMACAN INTERNATIONAL INC